Abivax SA reported a pooled clinical remission rate of 16.4% in two Phase 3 trials of its small molecule drug, obefazimod, for ulcerative colitis on 22 July, in one of the largest clinical development programmes for the disease ever conducted, The trials were eight-week induction studies and are being followed up by a maintenance trial which, if positive, will lead to a regulatory filing. Top-line results from the maintenance trial are expected in the second quarter of 2026, the company said.
